Drug profile · INN
siltuximab
SYLVANT
siltuximab (SYLVANT) is a interleukin-6 inhibitor. Associated with Recordati Rare Diseases Australia Pty.. Route of administration: injection. Current US regulatory status: approved.
Drug details — siltuximab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 15
- Data quality
- 0.84
Quick answer
siltuximab (SYLVANT) is a interleukin-6 inhibitor. Associated with Recordati Rare Diseases Australia Pty.. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-6 inhibitor
Primary target: Interleukin-6
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is siltuximab?
siltuximab (SYLVANT) is a interleukin-6 inhibitor. Associated with Recordati Rare Diseases Australia Pty.. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for siltuximab?
SYLVANT is a marketed brand name for siltuximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of siltuximab?
siltuximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.